

	• • • • •
	• • • • •
<b>ARIES</b> <sup>®</sup> SARS-CoV-2 (CE-IVD) Assay	
	$\bullet \bullet \bullet \bullet \bullet \bullet$
	• • • • • •
	• • • • • •
	• • • • •
	• • • • •

The ARIES<sup>®</sup> SARS-CoV-2 Assay is a real-time RT-PCR-based in vitro diagnostic test that qualitatively detects SARS-CoV-2 nucleic acid from nasopharyngeal swab (NPS) samples in UTM<sup>™</sup>, Liquid Amies (ESwab<sup>™</sup>), or equivalent.

### The ARIES<sup>®</sup> SARS-CoV-2 CE-IVD Assay offers:

- Fully Integrated Testing: Automate all aspects of testing, from sample preparation through analysis, in a self-contained cassette.
- Flexible Throughput: In two hours, process from 1 to 12 tests per batch; both STAT testing and medium volume sample batching are supported.
- A Versatile Portfolio: With a growing portfolio of cassette-ready assays and the tools to create laboratory developed tests (LDTs)\*, ARIES\* Systems deliver reliable detection for a wide range of testing needs.
- **Reliable Performance:** In addition to sensitive detection of SARS-CoV-2 through the ORF1ab and N gene targets, a sample processing control included in the cassette confirms result validity.

### Performance

A limit of detection (LoD) study was performed to evaluate the analytical sensitivity of the ARIES<sup>®</sup> SARS-CoV-2 Assay using one strain of the SARS-CoV-2, isolate USA-WA1/2020.

The confirmed ARIES SARS-CoV-2 Assay LoD concentration is 3.00 x 10<sup>3</sup> GCE/mL.

# Combined Clinical Performance of the ARIES® SARS-CoV-2 Assay for the SARS-CoV-2 Target

Reference Method Result	Number of Samples Tested	Positive	Negative	% Agreement with Reference Method	
Positive	89*	85	4†	РРА	95.5%
Negative	85	0	85	NPA	100.0%
Total	174				

\*Includes 30 contrived ESwab™ specimens.

<sup>†</sup>Three of the four false negative (FN) specimens were confirmed negative and one was positive for SARS-CoV-2 by PCR followed by bidirectional sequencing.

## Workflow



Due to its optimized PCR protocol, the ARIES® SARS-CoV-2 Assay cannot be run in the same magazine as other ARIES® CE-IVD assays.

## **Ordering Information**

Product Name	Part Number	
ARIES <sup>®</sup> SARS-CoV-2 Assay (24 Tests)	50-10051	
ARIES" Two Module System	ARIES-M12V1-IVD	
ARIES <sup>®</sup> M1 System	ARIES-M6V1-IVD	
SYNCT <sup>™</sup> Software	CN-SW47	

Products are CE Marked for IVD use.



# orders@luminexcorp.com or support@luminexcorp.com

For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at support@luminexcorp.com to obtain the appropriate product information for your country of residence. Validation of the LIS compatibility must be performed by the end user. ARIES<sup>®</sup> Systems are class 1(1) laser products.

\*Luminex does not endorse the use of any LDT for diagnostic use.

©2021 Luminex Corporation. All rights reserved. Luminex and ARIES are trademarks of Luminex Corporation, registered in the US and other countries. SYNCT is a trademark of Luminex Corporation. ESwab is a registered trademark of Copan Italia S.P.A.

#### luminexcorp.com

:	HEADQUARTERS				
÷	UNITED STATES	EUROPE	CANADA	CHINA	JAPAN
÷	+1 512 219 8020	+31 73 800 1900	+1 416 593 4323	+86 21 8036 9888	+81 3 5545 7440
÷	info@luminexcorp.com	europe@luminexcorp.com	info@luminexcorp.com	infocn@luminexcorp.com	infojp@luminexcorp.com

SS308164